CAR-T Could Be Worth Billions. Unless It Kills The Market First

For years, CAR-T has been one of the most exciting technologies in the world of medicine. It has already transformed the treatment of certain blood cancers, turning a patient's own immune cells into a weapon capable of hunting down malignant cells. Now, pharmaceutical companies want to take that same technology somewhere far bigger: autoimmune disease.

There is just one problem.

Novartis has paused eight clinical trials of its experimental CAR-T therapy, rapcabtagene autoleucel, after three patients died from complications of a severe immune reaction. The pause took effect on 24th August and covers immunology and neuroscience studies in conditions including lupus, systemic sclerosis, myositis, rheumatoid arthritis, myasthenia gravis and multiple sclerosis; oncology studies of the same therapy continue.¹ Bristol Myers Squibb has separately paused enrolment in autoimmune studies of its own CAR-T candidate, zolacabtagene autoleucel, after routine monitoring identified inflammatory events - which the company described as transient and reversible, with no deaths reported.²

The science has not necessarily failed. The economics, however, may have just become much more complicated.

Why Big Pharma Wants In

Pharmaceutical companies are interested in autoimmune CAR-T because the potential market is enormous.

CAR-T works by removing a patient's T-cells, genetically engineering them to recognise a specific target, multiplying them and then placing them back into the body. In cancer, this allows the immune system to attack malignant cells.

In autoimmune disease, researchers are attempting something more ambitious: reset the immune system itself.

This one therapy could potentially replace years of chronic therapy, which is precisely why investors are interested.

Autoimmune disease represents a much larger commercial opportunity than many of the cancers currently treated with CAR-T. A successful therapy could move cell therapy from a niche treatment for severely ill cancer patients into a potentially massive market.

And Big Pharma has been willing to pay for that possibility.

In October 2025, Bristol Myers Squibb agreed to acquire Orbital Therapeutics for $1.5 billion in cash, gaining access to an in-vivo CAR-T platform designed to generate therapeutic cells inside the patient's body.³

That deal is a signal about where pharmaceutical companies believe the future of CAR-T is heading.

They are not simply buying individual drugs.

They are buying the technology that might produce the next generation of drugs.

Then Comes the Hard Part

Biotech valuations are built on probabilities.

A company developing a drug today might generate billions of dollars in sales a decade from now. But to an investor, those billions are only worth something if the drug survives clinical trials, receives regulatory approval, reaches enough patients and can ultimately be sold at a price that justifies the cost of development.⁴

Every clinical trial therefore changes the value of the asset.

A positive result increases the probability of success; a safety signal can do the opposite.

This is why the recent CAR-T events matter beyond the individual patients and trials involved. Novartis' programme has not necessarily been killed. Bristol Myers Squibb has not abandoned autoimmune CAR-T. But the probability attached to their commercial ambitions has changed.

And as said above, in biotech, probability is valuation.

A drug expected to have a 70% chance of reaching the market is worth dramatically more than an otherwise identical drug with a 30% probability of success.

That means a safety problem can destroy billions in expected future value without a single dollar of current revenue disappearing.

The Cost of a Cure

There is another problem: CAR-T is expensive.

CAR-T requires specialised manufacturing, complex logistics and highly trained clinical teams. The patient must undergo cell collection, engineering, treatment and reinfusion - a centralised, patient-specific process that typically takes weeks and depends on an unbroken cold chain.⁵ That makes sense when the alternative is potentially dying from cancer.

It becomes much harder to justify when the patient has an autoimmune disease they may otherwise live with for another 40–50 years. This changes the risk-benefit calculation completely.

A patient with terminal cancer may accept a treatment carrying serious risks for the possibility of remission. A young patient may reasonably ask why they should accept a potentially fatal therapy when existing medicines can control their disease.

This means the commercial market for autoimmune CAR-T depends on something that is often overlooked in biotech valuations:

Patients actually wanting the treatment.

When Clinical Risk Becomes an M&A Problem

This creates a problem for pharmaceutical companies that have already spent billions positioning themselves for the next generation of cell therapy. The value of a biotech acquisition is rarely based on what the company generates today. It is based on what the buyer believes the technology could generate tomorrow. When clinical risk rises, that future becomes harder to price.

If companies can make CAR-T safer, they can potentially treat more patients. If they cannot, the addressable market shrinks. If the market shrinks, the billions spent acquiring these technologies become harder to justify.

This is where M&A becomes particularly interesting. BMS was not simply buying a single drug when it agreed to pay $1.5 billion for Orbital - the lead candidate, OTX-201, was still preclinical at the time of the deal. It was buying optionality: the possibility that the underlying technology could produce multiple therapies across multiple diseases.

That optionality can justify a substantial premium. But it also creates a different kind of risk. If the platform itself proves difficult to control, manufacture or commercialise, the buyer has not simply overpaid for one failed asset. It may have overpaid for the entire platform. The latest CAR-T safety concerns therefore matter far beyond the individual trials involved. They are a reminder that when pharma buys early-stage technology, it is ultimately buying a set of assumptions about clinical success, patient demand and future market size.

And suddenly, the problem is no longer purely clinical.

It is an M&A problem...

The Problem With a Perfect Cure

This is what makes autoimmune CAR-T so fascinating.

The question is no longer whether scientists can make T-cells powerful enough to reset the immune system.

They probably can.

The question is whether they can make them controlled enough, safe enough and cheap enough to turn that scientific breakthrough into a commercial one.

That distinction matters.

Final Thoughts

A therapy can be revolutionary and still be a terrible investment.

A company can have extraordinary clinical data and still be overvalued.

And a $1.5 billion acquisition can look visionary one year and expensive the next.

For now, the CAR-T story is still alive. The science is too promising for pharmaceutical companies to simply walk away.

But the latest trial pauses have exposed the industry's biggest weakness.

The most valuable CAR-T therapy may not be the one that can destroy the immune system. It may be the one that knows when to stop.

And whoever solves that problem could own one of the most valuable platforms in medicine.